CommercialCoverageMedium impact
08.01.68c, Inebilizumab-cdon (Uplizna®)
Independence Blue Cross·Neurology, Rheumatology·Pharmacy
Effective date
Mar 23, 2026
We identified it
Jun 19, 2026
Summary
The policy for Inebilizumab-cdon (Uplizna®) has been updated with changes to medical necessity criteria and medical coding requirements. This affects coverage and billing procedures for this specialty neurological medication used primarily for neuromyelitis optica spectrum disorders.
Action Required
Before March 23, 2026: Billing team must review and update medical necessity documentation requirements for Inebilizumab-cdon (Uplizna®) claims. Providers should ensure proper medical coding compliance per updated criteria. Contact pharmacy benefits team for specific documentation requirements to avoid claim denials.